Impact of Medicare Part D on Medicare-Medicaid Dual-Eligible Beneficiaries' Prescription Utilization and Expenditures
Impact of Medicare Part D on Medicare-Medicaid Dual-Eligible Beneficiaries' Prescription Utilization and Expenditures
复制标题
DOI：
10.1111/j.1475-6773.2009.01065.x
复制
发表时间：
2010-02-01
影响因子：
3.4
通讯作者：
Alexander, G. Caleb
中科院分区：
文献类型：
--
作者：
Basu, Anirban;Yin, Wesley;Alexander, G. Caleb
ObjectiveStudy on Part D on 65-78-year-old noninstitutionalized dual killbles ' prescription utilization and expenditures.Data SourceRandom sample of unique pharmacy customers of a national retail pharmacy chain who filled at least one prescription during both 2005 and 2006.对于每个受试者，我们获得了2005年1月1日至2007年4月31日期间填写的每个处方的索赔数据。研究设计广义估计方程用于检查“治疗”组的经验（1月1日，65岁至78岁之间的双杀，2005）与“控制”组的比较（1月1日医疗补助覆盖范围在60至63岁之间的近老年患者，2005年）在第一个18个月后，部分D实施。主要FindingsExpenditures治疗组和对照组密切跟踪对方在前D部分期间。在D部分执行之后，两组的支出立即下降，然后趋于平稳。有没有显着变化的趋势，在双杀'自付支出，每月总支出，药丸天，或处方总数由于部分D.ConclusionsWe发现没有证据表明，部分D不利影响药物利用或自付支出的双杀在过渡期内，也没有在16个月后，部分D实施。
ObjectiveTo examine the effect of Part D on 65-78-year-old noninstitutionalized dual eligibles' prescription utilization and expenditures.Data SourceRandom sample of unique pharmacy customers of a national retail pharmacy chain who filled at least one prescription during both 2005 and 2006. For each subject, we obtained claims data for every prescription filled between January 1, 2005, and April 31, 2007.Study DesignGeneralized estimating equations were used to examine the experience of a "treatment" group (dual eligibles between 65 and 78 years on January 1, 2005) with that of a "control" group (near-elderly patients with Medicaid coverage between 60 and 63 years on January 1, 2005) during the first 18 months after Part D implementation.Principal FindingsExpenditures for the treatment and control groups tracked each other closely in the pre-Part D period. Immediately following the implementation of Part D, expenditures for both groups decreased and then leveled off. There were no significant changes in trends in the dual eligibles' out-of-pocket expenditures, total monthly expenditures, pill-days, or total number of prescriptions due to Part D.ConclusionsWe find no evidence that Part D adversely affected pharmaceutical utilization or out-of-pocket expenditures of dual eligibles during the transition period, nor during the 16 months subsequent to Part D implementation.